Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study

Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). Materials and methods: A three-state partitioned survival model was developed to perform a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matthew Glover, Martyn Caplin, Oscar R. Leeuwenkamp, Louise Longworth
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Gastro-enteropancreatic neuroendocrine tumours (GEP-NETs) 177Lu-DOTA-octreotate [177Lu]Lu-DOTA-TATE Everolimus Sunitinib Quality-Adjusted Life Years (QALYs) Medicine R Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2b1a1faf067f47338bc56d82dd67197e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2b1a1faf067f47338bc56d82dd67197e
record_format	dspace
spelling	oai:doaj.org-article:2b1a1faf067f47338bc56d82dd67197e2021-11-12T04:27:47ZUse of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study1359-634910.1016/j.ejcsup.2021.06.003https://doaj.org/article/2b1a1faf067f47338bc56d82dd67197e2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1359634921000033https://doaj.org/toc/1359-6349Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). Materials and methods: A three-state partitioned survival model was developed to perform a cost-utility analysis of [177Lu]Lu-DOTA-TATE versus standard of care (high dose Octreotide LAR), everolimus and sunitinib. Effectiveness data for SoC, everolimus and sunitinib were obtained from published Kaplan–Meier survival curves. Given a lack of head-to-head effectiveness data, matching adjusted indirect comparisons (MAICs) were performed to population-adjust [177Lu]Lu-DOTA-TATE survival data based on prognostic factors and derive estimates of relative effectiveness. Health state utilities were estimated from real-world evidence. Drug acquisition costs were taken from nationally published sources (BNF, NICE), and administration costs were based on treatment protocols in [177Lu]Lu-DOTA-TATE studies, combined with nationally published unit costs (PSSRU, DoH reference costs). Incidence of adverse events were estimated using published sources. A discount rate of 3.5% was applied to both utilities and costs, and deterministic and probabilistic sensitivity analyses were performed. Costs were included from an NHS perspective and presented in 2017/18 GBP (and PPP Euros for base case). Results: In GI-NETs, the incremental cost-effectiveness ratio (ICER) of [177Lu]Lu-DOTA-TATE compared to SoC and everolimus was £26,528 (€27,672) and £24,145 (€25,186) per QALY, respectively. In P-NETs, the ICER of [177Lu]Lu-DOTA-TATE compared to SoC was £22,146 (€23,101) or £28,038 (€29,251) dependent on matched population, and £21,827 (€22,766) and £15,768 (€16,445) compared to everolimus and sunitinib, respectively. Conclusions: At a willingness to pay threshold of £30,000, [177Lu]Lu-DOTA-TATE is likely to be a cost-effective treatment option for GI-NET and P-NET patients versus relevant treatment comparators (NHS perspective).Matthew GloverMartyn CaplinOscar R. LeeuwenkampLouise LongworthElsevierarticleGastro-enteropancreatic neuroendocrine tumours (GEP-NETs)177Lu-DOTA-octreotate[177Lu]Lu-DOTA-TATEEverolimusSunitinibQuality-Adjusted Life Years (QALYs)MedicineRNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENEJC Supplements, Vol 16, Iss , Pp 14-23 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Gastro-enteropancreatic neuroendocrine tumours (GEP-NETs) 177Lu-DOTA-octreotate [177Lu]Lu-DOTA-TATE Everolimus Sunitinib Quality-Adjusted Life Years (QALYs) Medicine R Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Gastro-enteropancreatic neuroendocrine tumours (GEP-NETs) 177Lu-DOTA-octreotate [177Lu]Lu-DOTA-TATE Everolimus Sunitinib Quality-Adjusted Life Years (QALYs) Medicine R Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Matthew Glover Martyn Caplin Oscar R. Leeuwenkamp Louise Longworth Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
description	Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). Materials and methods: A three-state partitioned survival model was developed to perform a cost-utility analysis of [177Lu]Lu-DOTA-TATE versus standard of care (high dose Octreotide LAR), everolimus and sunitinib. Effectiveness data for SoC, everolimus and sunitinib were obtained from published Kaplan–Meier survival curves. Given a lack of head-to-head effectiveness data, matching adjusted indirect comparisons (MAICs) were performed to population-adjust [177Lu]Lu-DOTA-TATE survival data based on prognostic factors and derive estimates of relative effectiveness. Health state utilities were estimated from real-world evidence. Drug acquisition costs were taken from nationally published sources (BNF, NICE), and administration costs were based on treatment protocols in [177Lu]Lu-DOTA-TATE studies, combined with nationally published unit costs (PSSRU, DoH reference costs). Incidence of adverse events were estimated using published sources. A discount rate of 3.5% was applied to both utilities and costs, and deterministic and probabilistic sensitivity analyses were performed. Costs were included from an NHS perspective and presented in 2017/18 GBP (and PPP Euros for base case). Results: In GI-NETs, the incremental cost-effectiveness ratio (ICER) of [177Lu]Lu-DOTA-TATE compared to SoC and everolimus was £26,528 (€27,672) and £24,145 (€25,186) per QALY, respectively. In P-NETs, the ICER of [177Lu]Lu-DOTA-TATE compared to SoC was £22,146 (€23,101) or £28,038 (€29,251) dependent on matched population, and £21,827 (€22,766) and £15,768 (€16,445) compared to everolimus and sunitinib, respectively. Conclusions: At a willingness to pay threshold of £30,000, [177Lu]Lu-DOTA-TATE is likely to be a cost-effective treatment option for GI-NET and P-NET patients versus relevant treatment comparators (NHS perspective).
format	article
author	Matthew Glover Martyn Caplin Oscar R. Leeuwenkamp Louise Longworth
author_facet	Matthew Glover Martyn Caplin Oscar R. Leeuwenkamp Louise Longworth
author_sort	Matthew Glover
title	Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
title_short	Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
title_full	Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
title_fullStr	Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
title_full_unstemmed	Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
title_sort	use of [177lu]lu-dota-tate in the treatment of gastroenteropancreatic neuroendocrine tumours: results of a uk cost-effectiveness modelling study
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/2b1a1faf067f47338bc56d82dd67197e
work_keys_str_mv	AT matthewglover useof177luludotatateinthetreatmentofgastroenteropancreaticneuroendocrinetumoursresultsofaukcosteffectivenessmodellingstudy AT martyncaplin useof177luludotatateinthetreatmentofgastroenteropancreaticneuroendocrinetumoursresultsofaukcosteffectivenessmodellingstudy AT oscarrleeuwenkamp useof177luludotatateinthetreatmentofgastroenteropancreaticneuroendocrinetumoursresultsofaukcosteffectivenessmodellingstudy AT louiselongworth useof177luludotatateinthetreatmentofgastroenteropancreaticneuroendocrinetumoursresultsofaukcosteffectivenessmodellingstudy
_version_	1718431279941156864

Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study

Ejemplares similares